Pharmacoeconomic Considerations in the Management of Acute Tumor Lysis Syndrome

Semin Oncol. 2001 Apr;28(2 Suppl 5):19-22. doi: 10.1016/s0093-7754(01)90257-x.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Allopurinol / administration & dosage
  • Allopurinol / economics
  • Allopurinol / therapeutic use*
  • Antimetabolites / administration & dosage
  • Antimetabolites / economics
  • Antimetabolites / therapeutic use*
  • Cost-Benefit Analysis
  • Humans
  • Tumor Lysis Syndrome / drug therapy*
  • Tumor Lysis Syndrome / economics
  • Tumor Lysis Syndrome / prevention & control

Substances

  • Antimetabolites
  • Allopurinol